MX2019013574A - Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio. - Google Patents

Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio.

Info

Publication number
MX2019013574A
MX2019013574A MX2019013574A MX2019013574A MX2019013574A MX 2019013574 A MX2019013574 A MX 2019013574A MX 2019013574 A MX2019013574 A MX 2019013574A MX 2019013574 A MX2019013574 A MX 2019013574A MX 2019013574 A MX2019013574 A MX 2019013574A
Authority
MX
Mexico
Prior art keywords
sodium channels
deuterated
prodrugs
modulators
compounds
Prior art date
Application number
MX2019013574A
Other languages
English (en)
Inventor
Jiang Licong
Sabina Hadida Ruah Sara
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2019013574A publication Critical patent/MX2019013574A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos y sus sales farmacéuticamente aceptables, útiles como inhibidores de los canales de sodio. Los compuestos tienen la fórmula (I), en donde R es H o CH2OPO(OH)2. También se proporcionan composiciones farmacéuticas que comprenden los compuestos o sales farmacéuticamente aceptables y métodos para usar los compuestos, sales farmacéuticamente aceptables y composiciones farmacéuticas en el tratamiento de varios trastornos, incluyendo dolor.
MX2019013574A 2017-05-16 2018-05-16 Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio. MX2019013574A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762507172P 2017-05-16 2017-05-16
US201762547718P 2017-08-18 2017-08-18
PCT/US2018/032939 WO2018213426A1 (en) 2017-05-16 2018-05-16 Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels

Publications (1)

Publication Number Publication Date
MX2019013574A true MX2019013574A (es) 2019-12-18

Family

ID=62567801

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013574A MX2019013574A (es) 2017-05-16 2018-05-16 Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio.

Country Status (17)

Country Link
US (1) US11358977B2 (es)
EP (1) EP3625214B1 (es)
JP (1) JP7104070B2 (es)
KR (1) KR102714561B1 (es)
CN (1) CN110740993B (es)
AU (1) AU2018271110A1 (es)
BR (1) BR112019024016A2 (es)
CA (1) CA3063901A1 (es)
CL (1) CL2019003239A1 (es)
CO (1) CO2019013021A2 (es)
ES (1) ES2927712T3 (es)
IL (1) IL270680B (es)
MA (1) MA49137A (es)
MX (1) MX2019013574A (es)
UA (1) UA124857C2 (es)
WO (1) WO2018213426A1 (es)
ZA (1) ZA201907619B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202002971A (zh) * 2018-02-12 2020-01-16 美商維泰克斯製藥公司 治療疼痛的方法
AU2020205139A1 (en) * 2019-01-04 2021-08-19 Jiangsu Hengrui Medicine Co., Ltd. 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof
CN112996774B (zh) * 2019-01-25 2022-11-22 江苏恒瑞医药股份有限公司 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用
WO2020206119A1 (en) * 2019-04-02 2020-10-08 Vertex Pharmaceuticals Incorporated Process for making pyridone amides and prodrugs thereof useful as modulators of sodium channels
WO2020219867A1 (en) * 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
WO2021018165A1 (zh) * 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用
WO2021032074A1 (zh) * 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
AR120680A1 (es) 2019-12-06 2022-03-09 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CN114437062B (zh) * 2020-04-30 2024-05-17 成都海博为药业有限公司 一种可作为钠通道调节剂的化合物及其用途
CA3182633A1 (en) 2020-06-17 2021-12-23 Ashok Arasappan 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
CN113880771B (zh) * 2020-07-03 2023-09-19 福建盛迪医药有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
TW202214259A (zh) * 2020-08-19 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種選擇性ＮａＶ抑制劑的前藥及其晶型
TW202220962A (zh) * 2020-08-19 2022-06-01 大陸商江蘇恒瑞醫藥股份有限公司 選擇性NaV抑制劑的結晶形式及其製備方法
CN111808019B (zh) * 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN116964065A (zh) * 2021-02-26 2023-10-27 江苏恒瑞医药股份有限公司 一种选择性NaV抑制剂的可药用盐、结晶形式及其制备方法
JP7522943B2 (ja) 2021-05-07 2024-07-25 メルク・シャープ・アンド・ドーム・エルエルシー Ｎａｖ１．８阻害薬としてのシクロアルキル ３－オキソピペラジンカルボキサミド類及びシクロヘテロアルキル ３－オキソピペラジンカルボキサミド類
WO2022256679A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
WO2022256676A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
AU2022283934A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
AR126073A1 (es) 2021-06-04 2023-09-06 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio
BR112023025264A2 (pt) 2021-06-04 2024-02-20 Vertex Pharma Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida
AR126669A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
AR126670A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
EP4426290A1 (en) * 2021-11-02 2024-09-11 Schedule 1 Therapeutics, Inc. Use of cannabinoid compositions for treating pain associated with small fiber neuropathy
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AR129116A1 (es) 2022-04-22 2024-07-17 Vertex Pharma Compuestos de heteroarilo para el tratamiento del dolor
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
WO2002008748A2 (en) 2000-07-10 2002-01-31 Aurora Biosciences Corporation Ion channel assay methods
JP2003034671A (ja) 2001-05-17 2003-02-07 Nippon Nohyaku Co Ltd ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法
EP1490064B1 (en) 2002-02-14 2009-11-18 Pharmacia Corporation Substituted pyridinones as modulators of p38 map kinase
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
EP2332912A1 (en) 2003-08-08 2011-06-15 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenylderivates for use as sodium or calcium channel blockers in the treatment of pain
CA2574600C (en) 2004-07-23 2010-08-31 Pfizer Inc. Pyridine derivatives
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US8841483B2 (en) 2006-04-11 2014-09-23 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
MX2009003876A (es) 2006-10-12 2009-05-11 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos.
EP2183241B1 (en) 2007-05-03 2012-12-19 Pfizer Limited 2-pyridine carboxamide derivatives as sodium channel modulators
EP2212290B1 (en) 2007-10-11 2014-12-03 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
KR20100066583A (ko) 2007-10-11 2010-06-17 버텍스 파마슈티칼스 인코포레이티드 전압-개폐 나트륨 채널의 억제제로서 유용한 아미드
US8519137B2 (en) 2007-10-11 2013-08-27 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
WO2010049302A1 (en) 2008-10-29 2010-05-06 F. Hoffmann-La Roche Ag Novel phenyl amide or pyridil amide derivatives and their use as gpbar1 agonists
CN102264722B (zh) 2008-12-23 2014-04-02 霍夫曼-拉罗奇有限公司 作为p2x7调节剂的二氢吡啶酮酰胺
RU2518073C2 (ru) 2008-12-26 2014-06-10 ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. Новое бициклическое гетероциклическое соединение
MX2011012712A (es) 2009-05-29 2012-01-30 Raqualia Pharma Inc Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US8629149B2 (en) 2009-09-04 2014-01-14 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
EP2595989B1 (en) 2010-05-06 2016-07-13 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
CN103429571A (zh) 2010-12-22 2013-12-04 普渡制药公司 作为钠通道阻断剂的取代吡啶
WO2012106499A1 (en) 2011-02-02 2012-08-09 Vertex Pharmaceuticals Incorporated Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
US10385070B2 (en) 2011-02-18 2019-08-20 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
MX2013010067A (es) 2011-03-03 2014-01-31 Concert Pharmaceuticals Inc Derivados de compuestos de amino-heteroarilo sustituidos con pirazol.
US8828996B2 (en) 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
SI2753606T1 (sl) 2011-09-02 2017-10-30 Purdue Pharma Lp Pirimidini kot blokatorji natrijevih kanalov
CN103906746B (zh) 2011-10-26 2015-12-09 辉瑞有限公司 用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物
WO2013109521A1 (en) 2012-01-16 2013-07-25 Vertex Pharmaceuticals Incorporated Pyran-spirocyclic piperidine amides as modulators of ion channels
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
JP5823066B2 (ja) 2012-03-06 2015-11-25 ファイザー・インク 増殖性疾患の治療のための大環状誘導体
PT3239134T (pt) 2013-01-31 2021-01-28 Vertex Pharma Piridona amidas como moduladores dos canais de sódio
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
WO2014120815A1 (en) 2013-01-31 2014-08-07 Vertex Pharmaceuticals Incorporated Quinoline and quinazoline amides as modulators of sodium channels
US9108903B2 (en) 2013-01-31 2015-08-18 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
JP6337109B2 (ja) * 2013-07-19 2018-06-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルの調節剤としてのスルホンアミド
SI3080134T1 (sl) 2013-12-13 2018-11-30 Vertex Pharmaceuticals Incorporated Predzdravila piridon amidov uporabna kot modulatorji natrijevih kanalov
MA49566A (fr) 2017-07-11 2020-05-20 Vertex Pharma Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
TW202002971A (zh) 2018-02-12 2020-01-16 美商維泰克斯製藥公司 治療疼痛的方法

Also Published As

Publication number Publication date
CO2019013021A2 (es) 2020-04-01
CL2019003239A1 (es) 2020-04-17
WO2018213426A1 (en) 2018-11-22
JP2020519661A (ja) 2020-07-02
BR112019024016A2 (pt) 2020-06-09
JP7104070B2 (ja) 2022-07-20
EP3625214B1 (en) 2022-07-06
US20210155643A1 (en) 2021-05-27
IL270680B (en) 2022-06-01
MA49137A (fr) 2021-04-21
CN110740993B (zh) 2023-09-01
US11358977B2 (en) 2022-06-14
AU2018271110A1 (en) 2019-12-05
CA3063901A1 (en) 2018-11-22
EP3625214A1 (en) 2020-03-25
KR20200006128A (ko) 2020-01-17
ES2927712T3 (es) 2022-11-10
UA124857C2 (uk) 2021-12-01
KR102714561B1 (ko) 2024-10-10
CN110740993A (zh) 2020-01-31
ZA201907619B (en) 2022-03-30

Similar Documents

Publication Publication Date Title
MX2019013574A (es) Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio.
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
CR20220316A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
PH12015501661B1 (en) Pyridone amides as modulators of sodium channels
MX2021000781A (es) Profarmacos de amidas de piridona utiles como moduladores de canales de sodio.
MX2015009591A (es) Amidas como moduladores de canales de sodio.
NZ761388A (en) Methods of treatment for cystic fibrosis
MX2019013954A (es) Inhibidores covalentes de kras.
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
MX368833B (es) Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
AU2018243463A8 (en) 11,13-modified saxitoxins for the treatment of pain
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
MX2018007074A (es) Moduladores de canales de kv3 para tratar dolor.
MX2023014378A (es) N-(hidroxialquil(hetero)aril)tetrahidrofurano carboxamidas como moduladores de canales de sodio.
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
TN2018000214A1 (en) Alkyl dihydroquinoline sulfonamide compounds
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
EA201992719A1 (ru) Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов
MX2017011652A (es) (indazol-4-il)hexahidropirrolopirrolones y metodos de uso.
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов